



October 10, 2025

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 051

Scrip Code: 530019

Symbol: JUBLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a Press Release pertaining to the launch of New High-Speed Isolator based Line, at its Spokane Manufacturing Facility in the US by Jubilant HollisterStier LLC, USA, a wholly-owned subsidiary of the Company.

Date and Time of receipt - October 9, 2025, 8.36 pm (IST).

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



Jubilant Pharmova Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantpharmova.com

PRESS RELEASE

Jubilant HollisterStier LLC launches New High-Speed Isolator based Line, at its Spokane Manufacturing Facility in the US

Noida, India & Spokane, Washington, US - October 10, 2025 Jubilant Pharmova Limited announced today that Jubilant HollisterStier LLC (JHS)—a wholly owned subsidiary and a leading North American pharmaceutical contract manufacturer, specialising in sterile injectables and serving top global innovator pharma companies—successfully launched its New Sterile Fill & Finish line, third at its Spokane Manufacturing Facility in Washington, US. The launch was marked by the successful production of the inaugural batch, initiating revenue generation from the new Line. This milestone denotes a significant advancement in Jubilant HollisterStier’s multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility.

The New Line features advanced isolator technology designed to deliver enhanced sterility assurance, throughput and operational precision. Built to meet the highest global regulatory standards, the New Line significantly enhances the Company’s ability to support complex injectable programs across a broad range of therapeutic areas. The US\$ 132 million investment towards this New Third Line, reflects the Company’s long-term commitment to innovation, quality and supply chain resilience.

Together with the commissioning of its upcoming Fourth Line, JHS is on track to double its total sterile injectable manufacturing capacity at its Spokane facility in the US. This strategic investment further reinforces JHS’ leadership in domestic US pharmaceutical manufacturing. By expanding its infrastructure and increasing onshore capacity, the Company is contributing to US national health security and helping to reduce reliance on offshore supply chains—delivering a more resilient and agile pharmaceutical manufacturing ecosystem.

Commenting on the development, **Chris Preti, CEO - CDMO Sterile Injectables** said, *“Launching our Third Line is more than a milestone for us—it’s a defining moment in Jubilant HollisterStier’s journey. This expansion also reflects our deep-rooted commitment, to continued growth, technological excellence and the community at Spokane. With Third Line now operational and Fourth Line on the horizon, we are not just doubling our capacity, we’re building a future that will create hundreds of new jobs, strengthen the US pharmaceutical supply chain and reaffirm our role as a trusted partner in delivering life-saving therapies to patients around the world.”* He further added, *“In the wake of new tariffs imposed by the US Government, large innovator pharma companies are looking for high quality, US manufacturing facilities. Therefore, we are witnessing a very strong traction in Requests for Proposals (RFPs) for the New Line. We expect to reach the full utilisation for the New Line in the next 3 years.”*

Trusted by 5 of the top 20 global pharma companies as partners, JHS has a 92% customer retention rate that reflects high level of customer satisfaction. It also has a proven track-record, with regulatory organisations like the US FDA, EMA, PMDA Japan, Health Canada, ANVISA Brazil and other bodies in over 140 countries worldwide.

About Jubilant HollisterStier LLC

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a wholly-owned subsidiary of Jubilant Pharmova Limited. Jubilant HollisterStier is a leading Contract Development & Manufacturing Organisation specialising in comprehensive sterile fill-finish, lyophilization and ophthalmic manufacturing services. With decades of proven expertise and advanced facilities in Spokane, Washington, and Montréal, Québec, JHS delivers high-quality



pharmaceutical products to meet the rigorous standards of global healthcare markets and patients worldwide. Its flexible, collaborative partnership model empowers clients to accelerate speed to market while maintaining full regulatory confidence and manufacturing excellence.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with a global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in the manufacturing and supply of Radiopharmaceuticals with a network of 45 radiopharmacies in the US. The Company's Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant Pharmova Limited through its CDMO Sterile Injectables business offers manufacturing services including sterile fill and finish injectables (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. The CRDMO business of the Company includes the Drug Discovery Services business that provides contract research and development services through two world-class research centers in Bengaluru and Noida in India and one in France. The CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in the Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a 'Partner of Choice' by leading pharmaceuticals companies globally.

For more information, please contact:

For Investors

Pankaj Dhawan

Phone: +91 120 436 1105

E-mail: Pankaj.dhawan@jubl.com

Siddharth Rangnekar

CDR India

Phone: +91 97699 19966

E-mail: siddharth@cdr-india.com

For Media

Sandipan Ghatak

Phone: +91-98107 76182

E-mail: sandipan.ghatak@jubl.com

Jyoti Sharma

Ad Factors PR

Phone: +91 9810519900

E-mail: jyoti.sharma@adfactorspr.com

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.